share_log

Mangoceuticals | UPLOAD: Others

Mangoceuticals | UPLOAD: Others

Mangoceuticals | UPLOAD:其他
美股SEC公告 ·  04/30 13:03
Moomoo AI 已提取核心訊息
Mangoceuticals, Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on April 23, 2024, will not undergo review. The SEC's communication, dated April 30, 2024, was addressed to Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC has provided contact information for Juan Grana, a staff member in the Division of Corporation Finance, Office of Industrial Applications and Services.
Mangoceuticals, Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on April 23, 2024, will not undergo review. The SEC's communication, dated April 30, 2024, was addressed to Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC has provided contact information for Juan Grana, a staff member in the Division of Corporation Finance, Office of Industrial Applications and Services.
美國上市公司Mangoceuticals收到證券交易委員會(SEC)的消息,其於2024年4月23日提交的S-1表格註冊聲明將不會經過審查。SEC於2024年4月30日致函Mangoceuticals的首席執行官Jacob D. Cohen。該信函提醒公司及其管理層自行對其披露的準確性和充分性負責,而不論SEC的審查過程。SEC還提及了涉及加快註冊過程的規則460和461條。如需進一步查詢,請聯繫工業應用與服務辦公室,公司財務司的工作人員Juan Grana。
美國上市公司Mangoceuticals收到證券交易委員會(SEC)的消息,其於2024年4月23日提交的S-1表格註冊聲明將不會經過審查。SEC於2024年4月30日致函Mangoceuticals的首席執行官Jacob D. Cohen。該信函提醒公司及其管理層自行對其披露的準確性和充分性負責,而不論SEC的審查過程。SEC還提及了涉及加快註冊過程的規則460和461條。如需進一步查詢,請聯繫工業應用與服務辦公室,公司財務司的工作人員Juan Grana。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息